Gyeonggi-do, South Korea

Dongok Shin

USPTO Granted Patents = 4 

 

Average Co-Inventor Count = 9.7

ph-index = 1

Forward Citations = 3(Granted Patents)


Company Filing History:


Years Active: 2019-2023

Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents

Title: Innovations of Dongok Shin in Autoimmune Disease Treatment

Introduction

Dongok Shin is a prominent inventor based in Gyeonggi-do, South Korea. He has made significant contributions to the field of biopharmaceuticals, particularly in the treatment of autoimmune diseases. With a total of four patents to his name, his work focuses on innovative antibody therapies.

Latest Patents

One of Dongok Shin's latest patents is centered around an isolated anti-FcRn antibody. This antibody binds to the neonatal Fc receptor (FcRn), which has a high affinity for immunoglobulin G (IgG) or its fragments. The patent describes a method for preparing this antibody, as well as a composition for treating autoimmune diseases that includes the antibody. The FcRn-specific antibody binds to FcRn non-competitively with IgG, effectively reducing serum pathogenic auto-antibody levels. This innovative approach can be utilized for both the treatment and diagnosis of autoimmune diseases.

Career Highlights

Dongok Shin is currently associated with Hanall Biopharma Co., Ltd., where he continues to advance his research and development efforts. His work has been instrumental in creating new therapeutic options for patients suffering from autoimmune conditions.

Collaborations

He collaborates with notable colleagues, including Sung Wuk Kim and Seung Kook Park, to further enhance the impact of his research in the biopharmaceutical industry.

Conclusion

Dongok Shin's innovative work in developing antibody therapies for autoimmune diseases showcases his commitment to improving patient outcomes. His contributions to the field are significant and continue to pave the way for future advancements in biopharmaceuticals.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…